No Data
No Data
SciSparc's Subsidiary Advances in Lung Cancer Therapy
SciSparc Announces MitoCareX Confirms Potential Significant Role Of Its Drug Target In NSCLC
Express News | Scisparc: Mitocarex Confirms Potential Significant Role of Its Drug Target in Non-Small Cell Lung Cancer
SciSparc Eyes $6M Deal for Pain Treatment License
Express News | SciSparc Announced That It Has Signed A Non-binding Letter Of Intent With An Undisclosed Biotechnology Company To Pursue The Out-licensing Of Its SCI-160 Program For The Treatment Of Pain
Express News | Scisparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 Million
No Data
BFSkinner : Breakthru discovery
price tanks
102415025 : What is happening to this